2016 American Transplant Congress
Evaluation of Conformational Diversity of a Single HLA-I Molecule Coated on Single Antigen Beads: Potential Impact on Organ Allocation?
Terasaki Foundation Laboratory, Los Angeles, CA.
Recombinant HLA-I (rHLA-I) molecules are the antigenic targets used to screen HLA-I DSA in the sera of pre- or post-transplant patients. A conformational diversity, β2-microglobulin-associated…2015 American Transplant Congress
Targeting Leukocyte Integrin CD11b/CD18 With a Novel mAb Salvages Renal Function Following an Otherwise Irreversible Ischemic Insult in Cynomolgus Monkeys
Allograft dysfunction resulting from ischemic reperfusion injury (IRI) leads to increased peri-transplant costs, morbidity, and inferior long-term survival. Leukocyte/endothelial adhesion is an important pathway contributing…2015 American Transplant Congress
Eculizumab in the Treatment of Early Severe Acute Antibody Mediated Rejection Following HLA-Compatible Kidney Transplantation-Case Series
Severe early acute antibody-mediated rejection (AMR) is associated with poor allograft outcomes. Eculizumab is a humanized mouse monoclonal antibody against complement factor C5 that has…2015 American Transplant Congress
The Best Regimen With Rituximab for ABO-Incompatible Living Donor Liver Transplantation
Rituximab made a great progress on outcomes of ABO-incompatible living donor liver transplantation (ABO-I LDLT). Although Japanese multicenter study group published efficacy and safety of…2015 American Transplant Congress
Infectious Complications in ABO Incompatible Kidney Transplantation Recipient According to the Rituximab Dose
BackgroundDesensitization with rituximab and intravenous immunoglobulin improves ABO incompatible (ABOi) kidney transplantation (KT) outcomes. However, infections have been noted in association with rituximab administration. In…
- « Previous Page
- 1
- …
- 3
- 4
- 5